Public service announcement, it was found that he requires the Predictor long-term prostate cancer death

September 20, 2010
Public service announcement, it was found that he requires the Predictor long-term prostate cancer death
George Atkinson

A prostate specific antigen (PSA) at the age of 60 years a blood test can accurately predict the risk that a man may die from prostate cancer within the next 25 years, say researchers at Memorial Sloan-Kettering Cancer Center.could have important implications for determining which men should be screened after the age of 60 and which may not benefit from continued future prostate cancer screening.

The study analyzed blood samples from 1,167 men born in 1921 that were collected between 1981 and 1982. All  men were monitored until they had reached the age of 85 or had died. After studying different biomarkers, researchers found that the PSA level was a highly accurate predictor of long-term risk of prostate  cancer.In the study, 126 men were diagnosed with cancer of the prostate and of those, 90 percent of the deaths occurred in men in 25% of PSA levels at 60 years of edad.Los researchers concluded that men with a PSA level above 2 ng/ml at 60 years of age should be considered a higher risk of aggressive prostate cancer and must continue to be regularly reviewed.

Men with a PSA level below 1 ng/ml were 0.2% chance of death by cancer prostate. researchers concluded that men with PSA levels in this range, which is approximately half of all men, must be considered at low risk of death from prostate cancer and do not need to be projected in the future.

"Interestingly, the study also indicated that in some men it was found that in low-risk range may actually have prostate cancer; however is not likely to cause symptoms or shorten your life by the age of 85.""We know that [PSA] screening detects many prostate cancers are not harmful, leading to anxiety and therapy innecesario.Los researchers concluded that it is our ability to determine the risk of really aggressive cancers that makes this approach of this great potential value".

Relating to:
Experts Express doubts about the effectiveness of the PSA test
Routine prostate cancer not charitable detection
Test PSA doubtful benefits for elderly
Prostate Cancer: size matters...

Source: Memorial Sloan-Kettering Cancer Center

View the original article here